Neuropathologically, Alzheimer's disease (AD) is defined by the presence of plaques composed of the amyloid-beta (Abeta) protein. This alone makes identification of AD pathology in living subjects an important goal because it could allow refinement of early diagnosis and identification of pre-symptomatic pathology for use as a biomarker. In addition, the optimal development of new anti-amyloid therapies will require a means to monitor brain amyloid load. Our group has developed a novel amyloid-imaging positron emission tomography (PET) radiotracer termed """"""""Pittsburgh compound-B"""""""" (PIB) that, in proof-of-concept studies, performed well to distinguish AD from control subjects and localized in brain with a regional distribution consistent with that of the post-mortem distribution of plaques. While these results are exciting, certain basic and fundamental characteristics of this PIB PET technology must be further defined before this amyloid imaging technology can reach its potential as a diagnostic tool or a surrogate marker of efficacy. One of these fundamental characteristics is the variation of PIB retention (as a marker of amyloid load) across the full spectrum of disease severity in AD. This will be the focus of Project 1 of this Program Project (P01). To address this question, we will recruit 20 control subjects, 20 MCI patients, 20 mild and 20 moderate AD patients and 10 severe AD patients. All will be clinically evaluated and diagnosed by the University of Pittsburgh Alzheimer Disease Research Center and further evaluated with a neuropsychological battery through the P01 Clinical Core. All subjects will be studied cross-sectionally with a fully dynamic PIB PET scan. In addition, volumetric MRI and FDG PET will be performed so we can directly compare these current neuroimaging standards with the new PIB PET technology. Image analysis will be performed in the P01 Imaging, Methodology and Statistics Core. The control subjects, MCI and AD patients will be referred to Project 2 for the longitudinal studies and the control subjects also will serve as controls for Project 3. A simplified protocol will be used for the severe AD patients. The quantitative PIB PET data will be compared to neuropsychological measures to explore possible correlations between regional amyloid load and performance on function-specific cognitive testing (e.g. frontal or visuospatial tasks). The association of apolipoprotein-E genotype and education with PIB retention also will be explored. We hypothesize that PIB retention will be greater in subjects with more severe cognitive impairment through moderate AD and then plateau and that increased PIB retention will be of larger magnitude and will be detectable earlier than decreased hippocampal volume or decreased cerebral metabolic rate.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG025204-03
Application #
7423896
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
3
Fiscal Year
2007
Total Cost
$298,271
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Hu, Ziheng; Wang, Lirong; Ma, Shifan et al. (2018) Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y) 4:542-555
Zhao, Yujing; Tudorascu, Dana L; Lopez, Oscar L et al. (2018) Amyloid ? Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. JAMA Neurol 75:88-96
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95
Wilckens, Kristine A; Tudorascu, Dana L; Snitz, Beth E et al. (2018) Sleep moderates the relationship between amyloid beta and memory recall. Neurobiol Aging 71:142-148
Minhas, Davneet S; Price, Julie C; Laymon, Charles M et al. (2018) Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A? load. Neuroimage Clin 19:182-189
Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :
La Joie, Renaud; Ayakta, Nagehan; Seeley, William W et al. (2018) Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement :
Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750
Marquié, Marta; Normandin, Marc D; Meltzer, Avery C et al. (2017) Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 81:117-128
Mi, Zhiping; Abrahamson, Eric E; Ryu, Angela Y et al. (2017) Loss of precuneus dendritic spines immunopositive for spinophilin is related to cognitive impairment in early Alzheimer's disease. Neurobiol Aging 55:159-166

Showing the most recent 10 out of 106 publications